[go: up one dir, main page]

AU2002339169A1 - Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor - Google Patents

Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor

Info

Publication number
AU2002339169A1
AU2002339169A1 AU2002339169A AU2002339169A AU2002339169A1 AU 2002339169 A1 AU2002339169 A1 AU 2002339169A1 AU 2002339169 A AU2002339169 A AU 2002339169A AU 2002339169 A AU2002339169 A AU 2002339169A AU 2002339169 A1 AU2002339169 A1 AU 2002339169A1
Authority
AU
Australia
Prior art keywords
methylpropiono
toluidide
oestrogen
pvp
trifluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339169A
Inventor
Nicola Frances Bateman
Julie Kay Cahill
Neill Hugh Carman
Ian Derek Cockshott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of AU2002339169A1 publication Critical patent/AU2002339169A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002339169A 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor Abandoned AU2002339169A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103838A SE0103838D0 (en) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
SE0103838-9 2001-11-16
PCT/GB2002/005158 WO2003043630A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor

Publications (1)

Publication Number Publication Date
AU2002339169A1 true AU2002339169A1 (en) 2003-06-10

Family

ID=20286022

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339169A Abandoned AU2002339169A1 (en) 2001-11-16 2002-11-14 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor

Country Status (3)

Country Link
AU (1) AU2002339169A1 (en)
SE (1) SE0103838D0 (en)
WO (1) WO2003043630A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
HRP20060073B1 (en) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN101277682B (en) * 2005-07-28 2015-07-29 Isp投资有限公司 Amorphous efavirenz and production thereof
EP2125938A2 (en) 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
CN104146974B (en) * 2014-08-14 2016-09-07 杭州华东医药集团新药研究院有限公司 A kind of compositions containing letrozole and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4318371A1 (en) * 1993-05-28 1994-12-01 Schering Ag Agent containing a compound with antiandrogenic and a compound with competitive, progesterone-antagonistic effect
ES2307482T3 (en) * 1999-02-10 2008-12-01 Pfizer Products Inc. SOLID PHARMACEUTICAL DISPERSIONS.
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
DE60206889T2 (en) * 2001-02-27 2006-07-27 Astrazeneca Ab PHARMACEUTICAL FORMULATION CONTAINING BICALUTAMIDE
KR20030087048A (en) * 2001-04-02 2003-11-12 아스트라제네카 아베 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp

Also Published As

Publication number Publication date
WO2003043630A1 (en) 2003-05-30
SE0103838D0 (en) 2001-11-16

Similar Documents

Publication Publication Date Title
AU2002349001B2 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU2002349001A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
HUP0303454A3 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
MXPA03009410A (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant.
HUP0303644A3 (en) Pyridazinone-derivatives aldose reductase inhibitors, their use and pharmaceutical compositions containing them
AU2001291781A1 (en) Active ingredient combinations comprising insecticidal and acaricidal properties
WO2002089788A3 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
HUP0402028A3 (en) Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof
AU2002339169A1 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
AU2001265305A1 (en) Compositions containing hexitol and an antiproliferative agent
AU2002330233A1 (en) Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AU2003236076A1 (en) Hydrophilic polymers-flavonoids conjugates and pharmaceutical compositions comprising them
AUPR277401A0 (en) Physiologically active bracing
AUPR548601A0 (en) Pyrazolopyrazinecompound and pharmaceutical use thereof
AU2003283508A1 (en) .pharmaceutical composition comprising htless thansbgreater than4less than/sbgreater thandless thanspgreater than100less than/spgreater thana receptors, and therapeutic uses thereof
AU2002346860A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU2001243979A1 (en) Papaine containing pharmaceutical formulation resp. its use
AU2002245959A1 (en) An antioxidant composition and a cosmetic or pharmaceutical composition
AU2002345558A1 (en) Surface-doped plaster containing an active ingredient
AU2002247222A1 (en) (z)-styrylbenzylsulfones and pharmaceutical uses thereof
AU2002242909A1 (en) Pharmaceutical composition comprising ibuprofen and prochlorperazine
AU2002355890A1 (en) Active ingredient mixtures
AU2002244962A1 (en) Pyrazolecarboxamide derivative, intermediate therefor, and pest control agent containing the same as active ingredient

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase